After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

The terms need to be negotiated before Novavax’s vaccine could be granted full approval, the source said, declining to be named because they weren’t authorized to speak on behalf of the FDA.

Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. 35,180 people played the daily Crossword recently. Can you solve it faster than others?35,180 people played the daily Crossword ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax.